Search

Your search keyword '"BOGUNIEWICZ, Mark"' showing total 569 results
Start Over Author "BOGUNIEWICZ, Mark" Language english
569 results on '"BOGUNIEWICZ, Mark"'

1. A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology

Author

Lieberman, Jay A., Chu, Derek K., Ahmed, Tasnuva, Dribin, Timothy E., Abrams, Elissa M., Anagnostou, Aikaterini, Blumenthal, Kimberly G., Boguniewicz, Mark, Chase, Nicole M., Golden, David B.K., Hartog, Nicholas L., Heimall, Jennifer R., Ho, Tina, Lawrence, Monica G., Khan, David A., Minniear, Timothy Dean, Mustafa, S. Shahzad, Oppenheimer, John J., Phillips, Elizabeth J., Ramsey, Allison, Rider, Nicholas L., Schneider, Lynda, Shaker, Marcus S., Spergel, Jonathan M., Stone, Cosby A., Jr, Stukus, David R., Wang, Julie, and Greenhawt, Matthew J.

Published
2024
Full Text
View/download PDF

4. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE– and Institute of Medicine–based recommendations

Author

Chu, Derek K., Schneider, Lynda, Asiniwasis, Rachel Netahe, Boguniewicz, Mark, De Benedetto, Anna, Ellison, Kathy, Frazier, Winfred T., Greenhawt, Matthew, Huynh, Joey, Kim, Elaine, LeBovidge, Jennifer, Lind, Mary Laura, Lio, Peter, Martin, Stephen A., O'Brien, Monica, Ong, Peck Y., Silverberg, Jonathan I., Spergel, Jonathan M., Wang, Julie, Wheeler, Kathryn E., Guyatt, Gordon H., Capozza, Korey, Begolka, Wendy Smith, Chu, Alexandro W.L., Zhao, Irene X., Chen, Lina, Oykhman, Paul, Bakaa, Layla, Golden, David, Shaker, Marcus, Bernstein, Jonathan A., Horner, Caroline C., Lieberman, Jay, Stukus, David, Rank, Matthew A., Ellis, Anne, Abrams, Elissa, and Ledford, Dennis

Published
2024
Full Text
View/download PDF

5. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials

Author

Chu, Derek K., Chu, Alexandro W.L., Rayner, Daniel G., Guyatt, Gordon H., Yepes-Nuñez, Juan José, Gomez-Escobar, Luis, Pérez-Herrera, Lucia C., Díaz Martinez, Juan Pablo, Brignardello-Petersen, Romina, Sadeghirad, Behnam, Wong, Melanie M., Ceccacci, Renata, Zhao, Irene X., Basmaji, John, MacDonald, Margaret, Chu, Xiajing, Islam, Nazmul, Gao, Ya, Izcovich, Ariel, Asiniwasis, Rachel N., Boguniewicz, Mark, De Benedetto, Anna, Capozza, Korey, Chen, Lina, Ellison, Kathy, Frazier, Winfred T., Greenhawt, Matthew, Huynh, Joey, LeBovidge, Jennifer, Lio, Peter A., Martin, Stephen A., O’Brien, Monica, Ong, Peck Y., Silverberg, Jonathan I., Spergel, Jonathan M., Smith Begolka, Wendy, Wang, Julie, Wheeler, Kathryn E., Gardner, Donna D., and Schneider, Lynda

Published
2023
Full Text
View/download PDF

6. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials

Author

Chu, Alexandro W.L., Wong, Melanie M., Rayner, Daniel G., Guyatt, Gordon H., Díaz Martinez, Juan Pablo, Ceccacci, Renata, Zhao, Irene X., McMullen, Eric, Srivastava, Archita, Wang, Jason, Wen, Aaron, Wang, Fang Chi, Brignardello-Petersen, Romina, Izcovich, Ariel, Oykhman, Paul, Wheeler, Kathryn E., Wang, Julie, Spergel, Jonathan M., Singh, Jasvinder A., Silverberg, Jonathan I., Ong, Peck Y., O’Brien, Monica, Martin, Stephen A., Lio, Peter A., Lind, Mary Laura, LeBovidge, Jennifer, Kim, Elaine, Huynh, Joey, Greenhawt, Matthew, Gardner, Donna D., Frazier, Winfred T., Ellison, Kathy, Chen, Lina, Capozza, Korey, De Benedetto, Anna, Boguniewicz, Mark, Smith Begolka, Wendy, Asiniwasis, Rachel N., Schneider, Lynda C., and Chu, Derek K.

Published
2023
Full Text
View/download PDF

8. Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment

Author

Simpson, Eric L., Schlievert, Patrick M., Yoshida, Takeshi, Lussier, Stephanie, Boguniewicz, Mark, Hata, Tissa, Fuxench, Zelma, De Benedetto, Anna, Ong, Peck Y., Ko, Justin, Calatroni, Agustin, Rudman Spergel, Amanda K., Plaut, Marshall, Quataert, Sally A., Kilgore, Samuel H., Peterson, Liam, Gill, Ann L., David, Gloria, Mosmann, Tim, Gill, Steven R., Leung, Donald Y.M., and Beck, Lisa A.

Published
2023
Full Text
View/download PDF

15. Dietary Elimination for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis

Author

Oykhman, Paul, Dookie, Jared, Al-Rammahy, Husam, de Benedetto, Anna, Asiniwasis, Rachel N., LeBovidge, Jennifer, Wang, Julie, Ong, Peck Y., Lio, Peter, Gutierrez, Alvin, Capozza, Korey, Martin, Stephen A., Frazier, Winfred, Wheeler, Kathryn, Boguniewicz, Mark, Spergel, Jonathan M., Greenhawt, Matthew, Silverberg, Jonathan I., Schneider, Lynda, and Chu, Derek K.

Published
2022
Full Text
View/download PDF

16. Bleach baths for atopic dermatitis: A systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADE

Author

Bakaa, Layla, Pernica, Jeffrey M., Couban, Rachel J., Tackett, Kelly Jo, Burkhart, Craig N., Leins, Liz, Smart, Joanne, Garcia-Romero, Maria Teresa, Elizalde-Jiménez, Itzel Guadalupe, Herd, Michael, Asiniwasis, Rachel Netahe, Boguniewicz, Mark, De Benedetto, Anna, Chen, Lina, Ellison, Kathy, Frazier, Winfred, Greenhawt, Matthew, Huynh, Joey, LeBovidge, Jennifer, Lind, Mary Laura, Lio, Peter, O'Brien, Monica, Ong, Peck Y., Silverberg, Jonathan I., Spergel, Jonathan M., Wang, Julie, Begolka, Wendy Smith, Schneider, Lynda, and Chu, Derek K.

Published
2022
Full Text
View/download PDF

18. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis

Author

Boguniewicz, Mark, Beck, Lisa A., Sher, Lawrence, Guttman-Yassky, Emma, Thaçi, Diamant, Blauvelt, Andrew, Worm, Margitta, Corren, Jonathan, Soong, Weily, Lio, Peter, Rossi, Ana B., Lu, Yufang, Chao, Jingdong, Eckert, Laurent, Gadkari, Abhijit, Hultsch, Thomas, Ruddy, Marcella, Mannent, Leda P., Graham, Neil M.H., Pirozzi, Gianluca, Chen, Zhen, and Ardeleanu, Marius

Published
2021
Full Text
View/download PDF

20. Targeting the aryl hydrocarbon receptor as a strategy to expand the therapeutic armamentarium in atopic dermatitis.

Author

Eichenfield, Lawrence F., Silverberg, Jonathan I., Hebert, Adelaide A., and Boguniewicz, Mark

Subjects
ARYL hydrocarbon receptors, ATOPIC dermatitis, ECZEMA, COUGH, HERPES simplex
Abstract

This article discusses the burden of atopic dermatitis (AD), a chronic inflammatory skin disease that affects both children and adults. The incidence of AD is increasing globally, and it has a significant impact on quality of life. Current treatments have limitations, and there is a need for improved topical medications. Tapinarof, a nonsteroidal topical medication, has shown promise in clinical trials for patients with AD, including children as young as 2 years old. Targeting the aryl hydrocarbon receptor (AhR) may offer a novel therapeutic strategy for AD. The document provides a list of references and citations for further research on atopic dermatitis, covering various topics related to the condition and its treatment. [Extracted from the article]

Published
2024
Full Text
View/download PDF

23. 680 - Efficacy of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis by age of onset: analysis of two phase 3 clinical trials.

Author

Zirwas, Matthew J, Boguniewicz, Mark, Rosmarin, David, Fuxench, Zelma Chiesa, Warren, Richard B, Torres, Tiago, Bruin-Weller, Marjolein de, Dawson, Zach, Atwater, Amber Reck, Elmaraghy, Hany, Pierce, Evangeline, Bardolet, Laia, Zhong, Jinglin, and Armstrong, April W

Subjects
*CLINICAL trials, *GENETIC profile, *AGE of onset, *ATOPIC dermatitis, *LOGISTIC regression analysis
Abstract

Introduction/Background Atopic dermatitis (AD) has different clinical presentations, pathophysiology, comorbidity frequencies, and genetic profiles in adult-onset vs childhood-onset disease. Based on these differences, it is plausible that treatment response would also be different between adult- and childhood-onset AD. Lebrikizumab, a novel, high affinity monoclonal antibody, selectively targeting IL-13 with high affinity and slow dissociation rate, has been approved in the EU, UK, and Japan and is under investigation in the US and elsewhere for the treatment of moderate-to-severe AD. Objectives To evaluate the Week-16 efficacy of lebrikizumab monotherapy by age of AD onset in adults and adolescents with moderate-to-severe AD from ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967), identically-designed, randomized, double-blind, placebo-controlled phase 3 trials. Methods In ADvocate1 and ADvocate2, eligible patients were randomly allocated 2:1 to receive lebrikizumab 250 mg or placebo every 2 weeks. The date of AD onset was collected, and age of onset was calculated accordingly. Patients were stratified by age of AD-onset as ≤2, >2-to-<18, and ≥18 years. Efficacy was assessed at Week 16 with the proportion of patients with Investigator's Global Assessment score of 0 or 1 with ≥2-point improvement (IGA 0,1; the trials' primary endpoint); ≥75% (EASI 75) and ≥90% (EASI 90) improvement in the Eczema Area and Severity Index from baseline; ≥4-point Pruritus Numeric Rating Scale (NRS) improvement from baseline (with baseline score ≥4), and percentage change in total EASI from baseline. Data from patients who received topical or systemic rescue medication or discontinued treatment due to lack of efficacy were imputed as nonresponders or set to baseline values. Data from patients who discontinued treatment for other reasons were set to missing and analyzed by multiple imputation. This was a post-hoc analysis conducted on the modified, pooled intent-to-treat population. Treatment-by-age subgroup interaction was assessed with logistic regression. Binary outcomes were analyzed by the Cochran-Mantel-Haenszel method, and continuous outcomes were analyzed with ANCOVA. Results At baseline, the numbers of patients treated with lebrikizumab and placebo, respectively, were 215 and 117 in the ≤2 years AD-onset subgroup, 178 and 103 in the >2-to-<18 years subgroup, and 171 and 67 in the ≥18 years subgroup. At baseline, the percentages of patients with ≥1 atopic comorbidity were 81% in the ≤2 years subgroup, 74% in the >2-to-<18 years subgroup, and 58% in the ≥18 years subgroup. At Week 16, treatment-by-age subgroup interactions were not significant at the 0.10 level for IGA 0,1; EASI 75; EASI 90; and Pruritus NRS 4-pt improvement. Within each subgroup, a higher proportion of lebrikizumab-treated compared with placebo-treated patients (p<0.001) achieved IGA 0,1 responses (≤2 years: 41% vs. 12%; >2-to-<18 years: 35% vs. 12%; ≥18 years: 38% vs. 12%), EASI 75 responses (≤2 years: 57% vs. 17%; >2-to-<18 years: 51% vs. 16%; ≥18 years: 58% vs. 20%), and EASI 90 responses (≤2 years: 38% vs. 10%; >2-to-<18 years: 32% vs. 9%; ≥18 years: 33% vs. 8%). Additionally, the least-squares mean percentage change from baseline in total EASI score for lebrikizumab and placebo, respectively, was -65% and -26% in the ≤2 years subgroup, -60% and -26% in the >2-to-<18 years subgroup, and -63% and -30% in the ≥18 years subgroup (p<0.001 for lebrikizumab vs. placebo in all subgroups). The proportion of lebrikizumab-treated patients who reported ≥4-point improvement in Pruritus NRS from baseline (baseline ≥4) was greater compared with placebo-treated patients ([N]; ≤2 years: 43% [201] vs. 11% [108]; >2-to-<18 years: 41% [161] vs. 14% [96]; ≥18 years: 45% [154] vs. 12% [60]; p<0.001). Conclusions Regardless of age of AD onset, lebrikizumab was associated with significant improvements in AD signs and symptoms compared with placebo over 16 weeks of treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial

Author

Paller, Amy S., Bansal, Ashish, Simpson, Eric L., Boguniewicz, Mark, Blauvelt, Andrew, Siegfried, Elaine C., Guttman-Yassky, Emma, Hultsch, Thomas, Chen, Zhen, Mina-Osorio, Paola, Lu, Yufang, Rossi, Ana B., He, Xinyi, Kamal, Mohamed, Graham, Neil M. H., Pirozzi, Gianluca, Ruddy, Marcella, Eckert, Laurent, and Gadkari, Abhijit

Published
2020
Full Text
View/download PDF

29. Report from the National Institute of Allergy and Infectious Diseases workshop on “Atopic dermatitis and the atopic march: Mechanisms and interventions”

Author

Davidson, Wendy F., Leung, Donald Y.M., Beck, Lisa A., Berin, Cecilia M., Boguniewicz, Mark, Busse, William W., Chatila, Talal A., Geha, Raif S., Gern, James E., Guttman-Yassky, Emma, Irvine, Alan D., Kim, Brian S., Kong, Heidi H., Lack, Gideon, Nadeau, Kari C., Schwaninger, Julie, Simpson, Angela, Simpson, Eric L., Spergel, Jonathan M., Togias, Alkis, Wahn, Ulrich, Wood, Robert A., Woodfolk, Judith A., Ziegler, Steven F., and Plaut, Marshall

Published
2019
Full Text
View/download PDF

41. Tralokinumab therapy for moderate‐to‐severe atopic dermatitis: Clinical outcomes with targeted IL‐13 inhibition.

Author

Simpson, Eric L., Guttman‐Yassky, Emma, Eichenfield, Lawrence F., Boguniewicz, Mark, Bieber, Thomas, Schneider, Shannon, Guana, Adriana, and Silverberg, Jonathan I.

Subjects
ATOPIC dermatitis, ALLERGIC conjunctivitis, CLINICAL trials, TREATMENT effectiveness, MONOCLONAL antibodies, SYMPTOMS
Abstract

Atopic dermatitis (AD) is a chronic, inflammatory, intensely pruritic skin disorder associated with significant patient burden. Interleukin (IL)‐13 is a cytokine that acts as a driver of immune dysregulation, skin‐barrier dysfunction, and microbiome dysbiosis that characterizes AD, and is consistently overexpressed in AD skin. Tralokinumab is a fully human immunoglobulin (Ig) G4 monoclonal antibody that binds specifically to IL‐13 with high affinity, thereby inhibiting subsequent downstream IL‐13 signaling. Three pivotal phase 3 clinical trials demonstrated that tralokinumab 300 mg every other week, as monotherapy or in combination with topical corticosteroids as needed, provides significant improvements in signs and symptoms of moderate‐to‐severe AD, as measured by Investigator's Global Assessment 0/1 (clear/almost clear) and Eczema Area and Severity Index‐75 at Week 16. Improvements were observed soon after tralokinumab initiation and were maintained over 52 weeks of therapy. Tralokinumab significantly improved patient‐reported outcomes such as itch and sleep, and demonstrated a safety profile comparable with placebo; conjunctivitis during tralokinumab therapy was generally mild. Similar results were observed in a phase 3 adolescent trial. The role of IL‐13 in the pathophysiology of AD justifies a targeted approach and a wealth of clinical data supports tralokinumab as a new therapeutic option for people with moderate‐to‐severe AD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Tight junction defects in patients with atopic dermatitis

Author

De Benedetto, Anna, Rafaels, Nicholas M., McGirt, Laura Y., Ivanov, Andrei I., Georas, Steve N., Cheadle, Chris, Berger, Alan E., Zhang, Kunzhong, Vidyasagar, Sadasivan, Yoshida, Takeshi, Boguniewicz, Mark, Hata, Tissa, Schneider, Lynda C., Hanifin, Jon M., Gallo, Richard L., Novak, Natalija, Weidinger, Stephan, Beaty, Terri H., Leung, Donald Y.M., Barnes, Kathleen C., and Beck, Lisa A.

Published
2011
Full Text
View/download PDF

50. Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long‐term efficacy and patient‐reported outcomes.

Author

Simpson, Eric, Armstrong, April, Boguniewicz, Mark, Chiesa Fuxench, Zelma C., Feely, Meghan, Pierce, Evangeline, Sun, Luna, Chen, Yun‐Fei, Angle, Robinette, and Silverberg, Jonathan I.

Subjects
ATOPIC dermatitis, PATIENT reported outcome measures, TREATMENT effectiveness, BARICITINIB
Abstract

To address the need for long‐term efficacy and patient‐reported outcomes (PROs) data for patients with atopic dermatitis (AD) treated with baricitinib 2 mg, a study was conducted to evaluate the efficacy of baricitinib 2 mg in adult patients with moderate‐to‐severe AD. Data presented here provided efficacy and outcomes data for patients treated for 52 weeks. Patients who participated in the originating study, BREEZE‐AD5 (NCT03435081), and met additional eligibility criteria could enroll in the multicenter, open‐label, Phase 3, long‐term extension study BREEZE‐AD6 (NCT03559270). Patients received baricitinib 2 mg for the duration of BREEZE‐AD6. In BREEZE‐AD6, the proportion of patients who achieved a 75% improvement in the Eczema Area and Severity Index (EASI75) and validated Investigator Global Assessment for AD (vIGA‐AD™) of 0 (clear) or 1 (almost clear) were assessed through 52 weeks, in addition to several PROs. At week 52, the proportion of patients treated with baricitinib 2 mg daily achieving EASI75 was 48.6% (70/144), and 31.3% (45/144) of patients achieved a vIGA‐AD score of 0 or 1 (clear or almost clear). Improvements in PROs such as SCORing Atopic Dermatitis (SCORAD, itch and sleep) scores, Dermatology Life Quality Index (DLQI) total score, and DLQI ≤5 response were observed, and these responses were sustained through 52 weeks. Long‐term efficacy of baricitinib in patients with AD was demonstrated by both clinician and patient‐reported outcome measures. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results